Conclusion
toxicity, clear cell renal cell carcinoma, NCT03200587)Combination
CLEAR CELL RENAL CELL CARCINOMA
Combination therapy with avelumab and cabozantinib is safe and showed preliminary clinical activity in mccRCC. Even though the DLT was not met in any of the 3 cohorts, the recommended RP2D dose for the combination is cabozantinib 40 mg/day due to a high incidence of grade 2 toxicity for cabozantinib 60 mg/day after the DLT period. (ClinicalTrials.gov Identifier: NCT03200587)Combination immunotherapy is now considered standard first-line therapy for patients with metastatic clear cell renal cell carcinoma. This phase I trial assessed the safety and clinical activity of avelumab and cabozantinib combination therapy.